Related Experiment Video
Updated: May 7, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Vasculitis syndromes: RAVE about rituximab in ANCA vasculitis?
1Renal and Vascular Inflammation Section, Department of Medicine, Commonwealth Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
Abstract:
Follow-up data from the RAVE trial have shown that rituximab is as effective as immunosuppression with cyclophosphamide followed by azathioprine in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis. Rituximab is likely to become the standard of care for many patients with ANCA disease. However, an individualized approach is needed to identify those who require more-intense or prolonged therapy.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management
Cardiomyopathy IV: Restrictive Cardiomyopathy
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
